{"id":3127,"date":"2019-07-16T09:21:16","date_gmt":"2019-07-16T07:21:16","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=3127"},"modified":"2020-09-28T11:38:17","modified_gmt":"2020-09-28T09:38:17","slug":"biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/","title":{"rendered":"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-3128\" src=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2.png\" alt=\"\" width=\"536\" height=\"256\" \/><\/p>\n<p>BioDiscovery, investisseur europ\u00e9en de r\u00e9f\u00e9rence en capital-risque dans le domaine des Sciences de la Vie, g\u00e9r\u00e9 par Andera Partners, annonce aujourd&rsquo;hui avoir men\u00e9 au c\u00f4t\u00e9 de LSP la nouvelle lev\u00e9e de fonds de 133 millions de dollars (116 M\u20ac) de la soci\u00e9t\u00e9 AM-Pharma. Les fonds permettront de conduire une \u00e9tude clinique d\u2019enregistrement de son traitement innovant (recAP) chez des patients atteints d\u2019insuffisance r\u00e9nale aigu\u00eb caus\u00e9e par le sepsis. Ce tour de financement a \u00e9t\u00e9 conjointement men\u00e9 par les nouveaux investisseurs LSP et Andera Partners, aux c\u00f4t\u00e9s de l\u2019investisseur historique Forbion et des autres investisseurs existants Kurma Partners, Ysios Capital, ID Invest Partners, BB Pueros et Gilde Healthcare.<\/p>\n<p>L\u2019Insuffisance R\u00e9nale Aigu\u00eb (IRA) est une maladie d\u00e9vastatrice caract\u00e9ris\u00e9e par un taux de mortalit\u00e9 \u00e9lev\u00e9 et par l\u2019absence de traitements pharmacologiques sp\u00e9cifiques. Elle atteint chaque ann\u00e9e plusieurs millions de personnes dans le monde et est principalement caus\u00e9e par le sepsis, une maladie infectieuse et inflammatoire grave provoqu\u00e9e par l\u2019invasion de l\u2019organisme par des agents infectieux. En 2016, AM-Pharma a obtenu aupr\u00e8s de l\u2019agence de sant\u00e9 am\u00e9ricaine FDA (Food and Drug Administration) la d\u00e9signation \u00ab\u00a0Fast Track\u00a0\u00bb pour le d\u00e9veloppement de recAP, preuve du fort potentiel du produit en tant que traitement \u00ab\u00a0first-in-class\u00a0\u00bb de l\u2019IRA.<\/p>\n<p>Sur la base de r\u00e9sultats positifs de son essai clinique de phase II (STOP-AKI) qui a d\u00e9montr\u00e9 une am\u00e9lioration significative de la survie des patients et de leur fonction r\u00e9nale, AM-Pharma utilisera ces fonds pour mener une \u00e9tude internationale d\u2019enregistrement (SA-AKI) de recAP chez des nouveaux patients atteints d\u2019IRA caus\u00e9e par le sepsis. Pour rappel, les r\u00e9sultats de l&rsquo;\u00e9tude de phase II STOP-AKI, men\u00e9e aupr\u00e8s de 301 patients atteints d\u2019IRA caus\u00e9e par le sepsis, ont d\u00e9montr\u00e9 une r\u00e9duction significative et dose-d\u00e9pendante de la mortalit\u00e9 de plus de 40 % dans le groupe trait\u00e9 comparativement au groupe placebo. Bien que le crit\u00e8re principal de l\u2019\u00e9tude de phase II \u2013 am\u00e9lioration de la fonction r\u00e9nale \u00e0 court terme \u2013 n\u2019ait pas \u00e9t\u00e9 atteint, une am\u00e9lioration significative de la fonction r\u00e9nale \u00e0 long terme a \u00e9t\u00e9 observ\u00e9e. Par ailleurs, l\u2019\u00e9tude a permis de confirmer la robustesse du profil de s\u00e9curit\u00e9 et de tol\u00e9rance de recAP. Ces r\u00e9sultats ont \u00e9t\u00e9 publi\u00e9s dans la revue scientifique <em>Journal of the American Medical Association<\/em> (JAMA)<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>Ce nouveau tour de financement permettra de mener le plus important essai clinique jamais r\u00e9alis\u00e9 dans le domaine de l&rsquo;insuffisance r\u00e9nale aigu\u00eb, qui inclura pr\u00e8s de 1 400 patients r\u00e9partis dans plusieurs centres \u00e0 travers 12 pays. Apr\u00e8s de r\u00e9centes discussions avec les autorit\u00e9s r\u00e9glementaires aux \u00c9tats-Unis et en Europe, AM-Pharma estime qu\u2019en cas de succ\u00e8s, les r\u00e9sultats de cette \u00e9tude devraient permettre de d\u00e9poser un dossier d\u2019enregistrement du produit.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Erik van den Berg, PDG d&rsquo;AM-Pharma, commente :<\/strong> \u00ab\u00a0<em>Lever cette somme de capitaux aupr\u00e8s de fonds de capital-risque leaders dans le domaine des Sciences de la Vie \u2013 LSP et Andera Partners \u2013 suivis par l\u2019ensemble de nos actionnaires, souligne l&rsquo;urgence et le besoin m\u00e9dical sur lequel nous travaillons ainsi que le potentiel de recAP comme traitement innovant pour la vie des patients concern\u00e9s. Nous sommes impatients de travailler avec ce nouveau syndicat d&rsquo;investisseurs et de mener notre essai de phase III.\u00a0\u00bb<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Raphael Wisniewski, partenaire d&rsquo;Andera Partners, d\u00e9clare :<\/strong><em> \u00ab\u00a0Nous avons \u00e9t\u00e9 tr\u00e8s impressionn\u00e9s par le travail de d\u00e9veloppement qu\u2019AM-Pharma a r\u00e9alis\u00e9 jusqu\u2019\u00e0 pr\u00e9sent. Cela comprend aussi bien le d\u00e9veloppement que la fabrication de recAP bas\u00e9e sur les nouvelles r\u00e8gles d\u00e9finies par les bonnes pratiques de fabrication, la compr\u00e9hension du m\u00e9canisme d&rsquo;action du produit, la conception et la r\u00e9alisation d&rsquo;un essai clinique adaptatif de phase II et, surtout, son impact positif sur les patients. Ce processus a permis \u00e0 AM-Pharma de passer d&rsquo;une entreprise biopharmaceutique de stade pr\u00e9coce \u00e0 une entreprise biopharmaceutique en phase clinique et lui a permis de d\u00e9velopper une expertise pointue des causes de l\u2019insuffisance r\u00e9nale aigu\u00eb. Nous attendons avec impatience les r\u00e9sultats de l\u2019\u00e9tude qui, nous l\u2019esp\u00e9rons, se traduiront par la mise \u00e0 disposition d\u2019une nouvelle solution th\u00e9rapeutique pour les patients s\u00e9v\u00e8rement atteints. \u00bb<\/em><\/p>\n<p><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2710776?alert=article\">https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2710776?alert=article\u00a0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioDiscovery, investisseur europ\u00e9en de r\u00e9f\u00e9rence en capital-risque dans le domaine des Sciences de la Vie, g\u00e9r\u00e9 par Andera Partners, annonce aujourd&rsquo;hui avoir men\u00e9 au c\u00f4t\u00e9 de LSP la nouvelle lev\u00e9e de fonds de 133 millions de dollars (116 M\u20ac) de la soci\u00e9t\u00e9 AM-Pharma. Les fonds permettront de conduire une \u00e9tude clinique d\u2019enregistrement de son traitement&#8230;<\/p>\n","protected":false},"author":2,"featured_media":3128,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-3127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biodiscovery"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"BioDiscovery, investisseur europ\u00e9en de r\u00e9f\u00e9rence en capital-risque dans le domaine des Sciences de la Vie, g\u00e9r\u00e9 par Andera Partners, annonce aujourd&rsquo;hui avoir men\u00e9 au c\u00f4t\u00e9 de LSP la nouvelle lev\u00e9e de fonds de 133 millions de dollars (116 M\u20ac) de la soci\u00e9t\u00e9 AM-Pharma. Les fonds permettront de conduire une \u00e9tude clinique d\u2019enregistrement de son traitement...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-16T07:21:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-09-28T09:38:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"25\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP\",\"datePublished\":\"2019-07-16T07:21:16+00:00\",\"dateModified\":\"2020-09-28T09:38:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/\"},\"wordCount\":775,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/\",\"name\":\"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png\",\"datePublished\":\"2019-07-16T07:21:16+00:00\",\"dateModified\":\"2020-09-28T09:38:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png\",\"width\":300,\"height\":25},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/","og_locale":"fr_FR","og_type":"article","og_title":"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP - ANDERA PARTNERS","og_description":"BioDiscovery, investisseur europ\u00e9en de r\u00e9f\u00e9rence en capital-risque dans le domaine des Sciences de la Vie, g\u00e9r\u00e9 par Andera Partners, annonce aujourd&rsquo;hui avoir men\u00e9 au c\u00f4t\u00e9 de LSP la nouvelle lev\u00e9e de fonds de 133 millions de dollars (116 M\u20ac) de la soci\u00e9t\u00e9 AM-Pharma. Les fonds permettront de conduire une \u00e9tude clinique d\u2019enregistrement de son traitement...","og_url":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2019-07-16T07:21:16+00:00","article_modified_time":"2020-09-28T09:38:17+00:00","og_image":[{"width":300,"height":25,"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png","type":"image\/png"}],"author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP","datePublished":"2019-07-16T07:21:16+00:00","dateModified":"2020-09-28T09:38:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/"},"wordCount":775,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png","articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/","url":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/","name":"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png","datePublished":"2019-07-16T07:21:16+00:00","dateModified":"2020-09-28T09:38:17+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2019\/07\/AM-PHARMA-2-e1610017140874.png","width":300,"height":25},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/biodiscovery-mene-le-dernier-tour-de-table-de-116-me-dam-pharma-aux-cotes-de-lsp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"BioDiscovery m\u00e8ne le dernier tour de table de 116 M\u20ac d\u2019AM-Pharma aux c\u00f4t\u00e9s de LSP"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/3127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=3127"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/3127\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media\/3128"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=3127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=3127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}